Climb Bio, Inc. (CLYM) Investor Relations Documents

Climb Bio, Inc. (CLYM) investor relations documents from the company's IR site: 3 presentations, 16 press releases; latest deck 2026-08-14. Read in-app with summaries. First-party data.

Climb Bio Investor Presentation August 2026: Climb Bio presents its corporate strategy and pipeline, highlighting budoprutug for pMN, ITP, and SLE, and CLYM116 for IgAN, with significant 2026 data readouts.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-14	Presentation	Climb Bio Investor Presentation August 2026
2026-08-06	Press release	Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-06-11	Press release	Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocyto
2026-06-05	Press release	Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association
2026-05-26	Press release	Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
2026-05-14	Press release	Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
2026-05-12	Press release	Climb Bio to Present at Upcoming Investor Conferences
2026-05-07	Press release	Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-05	Presentation	Budoprutug and the CD19 Opportunity
2026-05-05	Press release	Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Medi
2026-04-28	Press release	Climb Bio, Inc. Announces $110.0 Million Private Placement
2026-04-08	Press release	Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
	Press release	Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
	Press release	Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
2025-09-29	Presentation	CLYM116 and the IgA Nephropathy (IgAN) Opportunity
	Press release	Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
	Press release	Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
	Press release	Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
	Press release	Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

CLYM overview · CLYM earnings · CLYM financials · CLYM KPIs · CLYM documents · CLYM ownership · CLYM peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.